Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Cited by 236

The DOI matches its Crossref record.

Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria

Open access
Llanos-Cuentas, Alejandro, Lacerda, Marcus V.G., Hien, Tran T., Vélez, Iván D., Namaik-larp, Chayadol, Chu, Cindy S., Villegas, Maria F., Val, Fernando, Monteiro, Wuelton M., Brito, Marcelo A.M., Costa, Mônica R.F., Chuquiyauri, Raul, Casapía, Martín, Nguyen, Chau H., Aruachan, Sandra, Papwijitsil, Ratchadaporn, Nosten, François H., Bancone, Germana, Angus, Brian, Duparc, Stephan, Craig, Graham, Rousell, Victoria M., Jones, Siôn W., Hardaker, Elizabeth, Clover, Donna D., Kendall, Lindsay, Mohamed, Khadeeja, Koh, Gavin C.K.W., Wilches, Viviana M., Breton, John J., Green, Justin A. · 2019 · New England Journal of Medicine

Abstract

BACKGROUND: Tafenoquine, a single-dose therapy for Plasmodium vivax malaria, has been associated with relapse prevention through the clearance of P. vivax parasitemia and hypnozoites, termed "radical cure." METHODS: We performed a phase 3, prospective, double-blind, double-dummy, randomized, controlled trial to compare tafenoquine with primaquine in terms of safety and efficacy. The trial was conducted at seven hospitals or clinics in Peru, Brazil, Colombia, Vietnam, and Thailand and involved patients with normal glucose-6-phosphate dehydrogenase (G6PD) enzyme activity and female patients with moderate G6PD enzyme deficiency; all patients had confirmed P. vivax parasitemia. The patients were randomly assigned, in a 2:1 ratio, to receive a single 300-mg dose of tafenoquine or 15 mg of primaquine once daily for 14 days (administered under supervision); all patients received a 3-day course of chloroquine and were followed for 180 days. The primary safety outcome was a protocol-defined decrease in the hemoglobin level (>3.0 g per deciliter or ≥30% from baseline or to a level of <6.0 g per deciliter). Freedom from recurrence of P. vivax parasitemia at 6 months was the primary efficacy outcome in a planned patient-level meta-analysis of the current trial and another phase 3 trial of tafenoquine and primaquine (per-protocol populations), and an odds ratio for recurrence of 1.45 (tafenoquine vs. primaquine) was used as a noninferiority margin. RESULTS: A protocol-defined decrease in the hemoglobin level occurred in 4 of 166 patients (2.4%; 95% confidence interval [CI], 0.9 to 6.0) in the tafenoquine group and in 1 of 85 patients (1.2%; 95% CI, 0.2 to 6.4) in the primaquine group, for a between-group difference of 1.2 percentage points (95% CI, -4.2 to 5.0). In the patient-level meta-analysis, the percentage of patients who were free from recurrence at 6 months was 67.0% (95% CI, 61.0 to 72.3) among the 426 patients in the tafenoquine group and 72.8% (95% CI, 65.6 to 78.8) among the 214 patients in the primaquine group. The efficacy of tafenoquine was not shown to be noninferior to that of primaquine (odds ratio for recurrence, 1.81; 95% CI, 0.82 to 3.96). CONCLUSIONS: Among patients with normal G6PD enzyme activity, the decline in hemoglobin level with tafenoquine did not differ significantly from that with primaquine. Tafenoquine showed efficacy for the radical cure of P. vivax malaria, although tafenoquine was not shown to be noninferior to primaquine. (Funded by GlaxoSmithKline and Medicines for Malaria Venture; GATHER ClinicalTrials.gov number, NCT02216123 .).

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1056/nejmoa1802537

Cites

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cited by

See all 236

Metadata

Authors
Llanos-Cuentas, A., Lacerda, M. V. G., Hien, T. T., Vélez, I. D., Namaik-larp, C., Chu, C. S., Villegas, M. F., Val, F., Monteiro, W. M., Brito, M. A. M., Costa, M. R. F., Chuquiyauri, R., Casapía, M., Nguyen, C. H., Aruachan, S., Papwijitsil, R., Nosten, F. H., Bancone, G., Angus, B., Duparc, S., Craig, G., Rousell, V. M., Jones, S. W., Hardaker, E., Clover, D. D., Kendall, L., Mohamed, K., Koh, G. C. K. W., Wilches, V. M., Breton, J. J., & Green, J. A.
Venue
New England Journal of Medicine
Published
2019-01-17
Volume
380
Issue
3
Pages
229-241
ISSN
  • 0028-4793 (ISSN-L)
  • 1533-4406
OpenAlex
W2910452042
Cited by
236
References
0
FWCI
27.04
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. https://app.cochat.ai/papers/10.1056/nejmoa1802537
The paper
Llanos-Cuentas, A., Lacerda, M. V. G., Hien, T. T., Vélez, I. D., Namaik-larp, C., Chu, C. S., Villegas, M. F., Val, F., Monteiro, W. M., Brito, M. A. M., Costa, M. R. F., Chuquiyauri, R., Casapía, M., Nguyen, C. H., Aruachan, S., Papwijitsil, R., Nosten, F. H., Bancone, G., Angus, B., . . . Green, J. A. (2019). Tafenoquine versus Primaquine to Prevent Relapse of Plasmodium vivax Malaria. New England Journal of Medicine. https://doi.org/10.1056/nejmoa1802537

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.